The Cerenovus BRAVO Flow Diverter will divert blood flow from the aneurysm and promote healing thereby reducing the risk of rupture, a main cause of hemorrhagic stroke.
With this product, Cerenovus is making entry into the flow diverter market and this product will become part of it board array of devices used in endovascular treatment of hemorrhagic and ischemic stroke.
Cerenovus claims that the device has been designed with the aim of improving clinician ease of use, to improve cost effectiveness and to reduce the length of procedure.
Stroke can be a devastating disease that strikes nearly 15 million people each year and hemorrhagic strokes account for nearly 13% of all strokes. Aneurysms are the main cause of hemorrhagic strokes and occur when a weakened region of a blood vessel balloons until it ruptures and bleeds into the brain.
Cerenovus worldwide president Daniella Cramp said: “The BRAVO Flow Diverter builds on our legacy of providing meaningful innovation to enable patients to live a life free from the burden of stroke.
“Our entry into the flow diverter market demonstrates our commitment to push the boundaries of stroke treatment and marks a key step towards changing the trajectory of stroke.”
Karolinska University Hospital Neurointerventionalist senior consultant and evaluator for BRAVO Flow Diverter Patrick Brouwer stated that flow diverters are now being used widely and for many, it has now become the go-to option for treating complex aneurysms.
“I believe the design of the BRAVO Flow Diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms,” Brouwer said.
Cerenovus, which offers neurovascular care, aims to change the trajectory of stroke by helping physicians protect people from a lifetime of hardship.
The company offers a portfolio of devices used in endovascular treatment of hemorrhagic and ischemic stroke.
